Price reductions for several drugs

Several pharmaceutical products will see their prices decrease at the beginning of 2027, according to a notice on pharmaceutical product prices published in the Official Journal on November 3, 2026.

Stelara's price drops by 10 percent

The price of Stelara (ustekinumab, Janssen) 45 mg or 90 mg will see its public price with tax (TTC) decrease by approximately 10 percent, to 1,347.24 euros for a vial, a prefilled pen, or a prefilled syringe, regardless of the dosage.

Biosimilars entering the market

The price decrease occurs as the reference drug has seen the arrival of several biosimilars: Imuldosa (Accord), Otulfi (Fresenius Kabi), Pyzchiva (Sandoz), Steqeyma (Celltrion Healthcare), Usrenty (EG Labo), Wezenla (Amgen), and Yesintek (Biocon Biologics).

Helikit's price drops by 7 percent

The Official Journal also publishes, starting January 1, 2027, a 7 percent decrease in the price of Helikit (urea, Mayoly Spindler), indicated in the initial diagnosis and post-treatment eradication control of Helicobacter pylori. The kit will be priced at 27.44 euros.

Suvreza's price reduction

The fixed-dose hypocholesterolemic combination Suvreza (rosuvastatin + ezetimibe, Sanofi) will also see its prices decrease to 14.39 euros for 30 tablets and 40.71 euros for 90 tablets, regardless of the dosage, 10 mg/10 mg or 20 mg/10 mg.

Kisplyx's 30 percent price cut

Finally, starting January 2, 2027, the price of Kisplyx (lenvatinib, Eisai), a treatment for advanced renal cell carcinoma, will decrease by 30 percent, to 908.31 euros for 30 capsules at 4 mg or 10 mg.